Perturbations to mammalian SWI/SNF (mSWI/SNF or BAF) complexes contribute to more than 20% of human cancers, with driving roles first identified in malignant rhabdoid tumor, an aggressive pediatric cancer characterized by biallelic inactivation of the core BAF complex subunit SMARCB1 (BAF47). However, the mechanism by which this alteration contributes to tumorigenesis remains poorly understood. We find that BAF47 loss destabilizes BAF complexes on chromatin, absent significant changes in complex assembly or integrity. Rescue of BAF47 in BAF47-deficient sarcoma cell lines results in increased genome-wide BAF complex occupancy, facilitating widespread enhancer activation and opposition of Polycomb-mediated repression at bivalent promoters. We demonstrate differential regulation by two distinct mSWI/SNF assemblies, BAF and PBAF complexes, enhancers and promoters, respectively, suggesting that each complex has distinct functions that are perturbed upon BAF47 loss. Our results demonstrate collaborative mechanisms of mSWI/SNF-mediated gene activation, identifying functions that are co-opted or abated to drive human cancers and developmental disorders.
Chromatin regulation is critical for the maintenance of timely and appropriate gene expression, with epigenetic regulators playing key parts in both normal development and oncogenesis 1 . Chromatin remodeling complexes regulate DNA accessibility via alteration of nucleosome positioning and/or occupancy in an ATP-dependent manner 2 . One of the most well-characterized chromatin remodeling complexes is the mSWI/SNF (BAF) complex, first identified in yeast 3 and subsequently characterized in Drosophila 4 and mammals 5 . Specialized BAF complex subunit configurations are critical in pluripotency 6, 7 and neural differentiation 8 , as well as the development of several other adult tissue types 9 . Various epigenetic modifiers and chromatin remodeling complexes, including BAF complexes, have been shown to localize to active promoters and enhancers in embryonic stem cells 10, 11 ; however, the roles for specific complexes in the establishment and maintenance of promoter and enhancer states are not well understood.
Evidence for a driving role of BAF complex alterations in cancer was first documented in malignant rhabdoid tumor (MRT), a highly aggressive pediatric cancer 12 in which the SMARCB1 gene, which encodes the core BAF complex subunit BAF47 (also known as INI1 and hSNF5), undergoes biallelic inactivation in ~98% of MRT cases 12, 13 . BAF47 loss has since been shown to be the hallmark genetic alteration in additional cancer types, including atypical teratoid/rhabdoid tumor (AT/RT; ~100%) 14 and epithelioid sarcomas (EpS; >90%) 15 . Additionally, BAF47 alterations are implicated in the development of meningiomas 16 , schwannomatosis 17 , and Coffin-Siris syndrome 18 . MRTs are genomically stable sarcomas with extremely low mutational burden 19, 20 , and conditional biallelic inactivation of Smarcb1 in mice leads to the most rapid tumorigenesis documented for a single gene deletion, with median onset at 11 weeks 21 . Recent exome-sequencing studies have demonstrated that genes encoding BAF complex subunits are mutated in >20% of human cancers 22 , including gain-offunction perturbations such as the SS18-SSX oncogenic fusion, a hallmark of ~100% of synovial sarcomas 23 . The clear link between SMARCB1 deletion and MRT suggests MRT as a uniquely powerful disease setting in which to understand BAF complex alterations across human cancer.
Dynamic opposition between BAF complexes and Polycomb repressive complexes was first demonstrated genetically in Drosophila 4, 24 and has since been shown to govern critical processes in both normal development and disease 25 . In mammals, this opposition has been suggested to occur both in a locus-specific manner 26, 27 and in a global regulatory manner through upregulation of Ezh2 (ref. 28) . In synovial sarcoma, the oncogenic SS18-SSX fusion has been demonstrated A r t i c l e s to direct BAF complexes to new genomic loci such as SOX2, opposing Polycomb-mediated repression and leading to oncogene activation 23 . More recently, mechanistic studies have demonstrated that BAF-Polycomb complex opposition occurs on chromatin in a rapid, ATP-dependent manner, with loss of BAF47 leading to significant diminution in the ability of BAF complexes to oppose Polycombmediated repression 29 . PRC2 complexes have particularly critical roles in maintaining bivalent gene promoters, marked dually by trimethylation of histone H3 Lys4 (H3K4me3) and H3K27me3 (refs. 30,31) . The bivalent state of a given locus is maintained by a balance between activating trithorax (Trx) proteins (such as mixedlineage leukemia proteins (MLLs)) and repressive Polycomb group (PcG) proteins (such as PRC2 components) 32 , with several BAF complex subunits also categorized as Trx-group proteins 24 . Loss of PRC2 leads to activation of tissue-specific bivalent promoters but not monovalent promoters marked by H3K27me3 only 33 . Preclinical studies (and now early-stage clinical studies) using EZH2 inhibitors in BAF47-deficient sarcoma model systems have begun to show promise 34 , suggesting that this dynamic opposition is a critical mediator of oncogenesis in BAF47-deficient sarcomas.
We sought to understand how loss of BAF47, a core BAF complex subunit, affects the stability, targeting, and gene expression regulation of BAF complexes in sarcomas. We determined that loss of BAF47 destabilizes the association of BAF complexes on chromatin without greatly impairing complex stability or assembly. Rescue of BAF47 in MRT and EpS cell lines drives a major gain of genome-wide BAF complex occupancy and enhancer state activation across the genome. In addition, we found that rescue of BAF47 targets BAF complexes to bivalent promoters, enabling opposition of Polycomb-mediated repression to resolve bivalent promoters to activation. The enhancer activation and resolution of bivalent promoters observed are collaborative with respect to gene expression, suggesting dual complementary roles in for BAF47-mediated tumor suppression. These data suggest two defining functions of BAF complexes that can be singly or collaboratively perturbed in BAF complex-altered cancers and developmental disorders.
RESULTS

BAF47 loss decreases chromatin affinity of BAF complexes
BAF47 is stable in its association with the BRG1 ATPase subunit in over 2 M urea treatment 23 . To determine the effect of BAF47 loss on the integrity and subunit stability of BAF complexes, we infected G401 MRT cells with a lentiviral vector encoding full-length BAF47 or an empty vector control (Fig. 1a) . Nuclear protein levels of core BAF subunits, both total and BAF-bound, were largely unchanged upon rescue of BAF47 (Fig. 1b and Supplementary Fig. 1a) . To confirm this, we generated SMARCB1 ∆/∆ HEK293T cells using CRISPR-Cas9-mediated gene editing knockout and again did not observe changes in either total or BAF complex-bound protein levels (Fig. 1c) . Silver stain analyses of anti-BRG1 and anti-BAF250A IPs from nuclear protein showed highly similar banding patterns in both conditions ( Fig. 1d and Supplementary Fig. 1b) . To complement this, we used low-stringency anti-BRG1 affinity purification-proteomic mass spectrometry ( Fig. 1e and Supplementary Table 1) . The abundance of peptides corresponding to most BAF complex subunits was roughly equivalent in both conditions, with the exception of the BAF45A, BAF45D and BAF60C subunits, which showed increases upon BAF47 rescue, possibly indicating their direct tethering to BAF47. Prior studies examining changes in complex subunit composition upon loss of the BAF47 subunit have presented conflicting results; some showed dissociation of BAF complexes 35, 36 and others suggested no changes to BAF complex assembly 29, [37] [38] [39] , probably owing to differences in chromatin-bound protein purification methods and effects of super-stoichiometric protein abundance resulting from strong overexpression. Additionally, the harsh denaturing detergents, such as SDS and sodium deoxycholate, used in some of these prior experiments can disrupt protein-protein complex interactions and/or reduce the antibody pulldown efficacy in solution (Supplementary Fig. 1e,f) .
To examine changes to the biochemical stability and size of BAF complexes, we performed 10-30% glycerol gradient-based density sedimentation analyses of nuclear extracts from G401 cells treated with empty vector or BAF47 lentiviral vector (below referred to as empty or BAF47 conditions, respectively) (Fig. 1f,g and Supplementary  Fig. 1c) . We found that BAF47 fully incorporated into BAF complexes upon re-expression (Fig. 1g, fractions 13-15) , and subunits corresponding to both BAF and PBAF complexes shifted up by approximately 1-2 fractions, in accordance with the expected gain in complex mass resulting from BAF47 and associated subunits (Fig. 1e) . Select subunits, including BRG1 and BAF60A, showed a greater spread across gradient fractions in the absence of BAF47; however, BRG1-bound subunit stability was largely retained, as demonstrated by urea denaturation experiments (Supplementary Fig. 1d ). Collectively, these results demonstrate that loss of BAF47 does not affect global protein abundance or complex incorporation of most BAF complex subunits, nor does it render the complex wholly unstable in solution, as might have been predicted given its high degree of evolutionary conservation and highly penetrant loss-of-function phenotype.
As BAF chromatin remodeling complexes contain several DNAand histone-binding domains, we sought to determine whether BAF47 loss alters the stability of BAF complexes on chromatin. We used NaCl-based differential salt extraction to determine the relative affinity of BAF complex proteins on chromatin in G401 cells in either empty or BAF47 conditions ( Fig. 1h and Supplementary  Fig. 2a) . We found that BAF47-deficient complexes in G401 cells dissociate from chromatin at NaCl concentrations between 150 and 300 mM, whereas subunits dissociate from chromatin at 500-1,000 mM NaCl treatment upon BAF47 rescue (Fig. 1h,i and Supplementary Fig. 2b,c) . We assessed PRC2 subunits EZH2 and SUZ12 as controls and observed no changes in chromatin dissociation between conditions ( Supplementary Fig. 2d ). Results were similar in comparing BAF complex chromatin affinity in wild-type and SMARCB1 ∆/∆ HEK293T cells (Supplementary Fig. 2e-g ). These results indicate that the primary biophysical consequence of BAF47 loss is decreased affinity of BAF complexes for chromatin, suggesting alterations in their genome-wide chromatin occupancy and regulatory capacity.
BAF47 rescue drives widespread BAF complex occupancy gain
To examine the effect of BAF47 rescue on BAF complex targeting and gene regulation, we infected two MRT cell lines, TTC1240 and G401, with lentiviral vectors (empty control or encoding BAF47) (Fig. 2a) and performed chromatin IP of BAF complexes followed by sequencing (ChIP-seq) using antibodies to two core BAF complex subunits, BRG1 and BAF155. We observed a gain of genome-wide BAF complex occupancy upon rescue of BAF47 in TTC1240 cells (Fig. 2b-d and Supplementary Fig. 3a-e) . We found that gained (BAF47-only) BAF complex sites (defined as shared BRG1-BAF155 sites) in TTC1240 cells were disproportionately localized to promoterdistal regions, as compared to conserved BAF complex sites empty-BAF47 shared ( Fig. 2e and Supplementary Fig. 3f,g ). Gained BAF complex sites were selectively enriched for unique motifs such as the AP-1 motif (Fig. 2f and Supplementary Fig. 3h ). In addition, weexamined the 46-way vertebrate PhyloP evolutionary conservation scores at all conserved and gained BAF complex sites upon BAF47 reintroduction in TTC1240 cells and found that gained sites were much less evolutionarily conserved than conserved sites (Fig. 2g) . This pattern was observed at both proximal and distal BAF complex sites ( Supplementary Fig. 3i,j) 
A r t i c l e s
AT/RT (two lines), to BAF47 rescue (Supplementary Table 2 ). In all MRT and AT/RT cell lines assessed, we found marked proliferative arrest upon BAF47 rescue; however, this occurred in only one of the EpS cell lines, with the three others showing no significant proliferative arrest upon BAF47 rescue ( Fig. 2h and Supplementary Fig. 4 ).
To validate our genome-wide findings from TTC1240 cells and to decouple changes from BAF47 reintroduction and subsequent proliferative suppression, we performed ChIP-seq for BRG1 and BAF155 in G401 cells as well as in the HS-ES-2M and VA-ES-BJ EpS lines. We observed a similar gain in BAF complex occupancy upon BAF47 rescue to promoter-distal sites, irrespectively of the cell line used (Fig. 2i-k and Supplementary Fig. 5 ). These data demonstrate that reintroduction of the BAF47 subunit drives a consistent, widespread gain of genome-wide BAF complex occupancy across distinct BAF47-deficient sarcoma subtypes, independently of sensitivity to BAF47-mediated growth suppression. 
A r t i c l e s BAF complex-mediated enhancer activation requires BAF47
To determine the effect of gained BAF complex occupancy on the histone landscape, we performed ChIP-seq studies for H3K4me3, H3K4me1, and acetylation of H3K27 (H3K27ac). Notably, we found substantial gains in H3K27ac and H3K4me1, but very minor changes in H3K4me3 levels in TTC1240 cells (Fig. 3a) , suggesting that gained BAF complex occupancy predominantly determines both enhancer state and enhancer activation 40 . We found that this activation was specific to distal enhancer sites ( Fig. 3b-d ) and observed similar gains in enhancer activation across all cell lines studied ( Supplementary Fig. 6 ).
In addition, we noted the presence of enhancer sites that retained BAF complex occupancy and activation irrespectively of BAF47 status, suggesting alternate activators at these sites. We found a strong correlation between the log 2 fold change in occupancy of BRG1 and H3K27ac (Pearson correlation coefficient (PCC) = 0.82) over all TTC1240 BAF sites (in both control and BAF47 conditions), and a lower but strong correlation with H3K4me1 (PCC = 0.56), likely owing to mark abundance; we observed minimal correlations with H3K4me3 (PCC = 0.15) (Fig. 3e and Supplementary Fig. 7a-c) .
These results indicate that in addition to BAF complex-mediated enhancer state and activation, the levels of BAF complex occupancy correspond directly to degree of enhancer activation. Connecting BAF47-mediated enhancer gain to gene expression, we find that the number of gained distal BAF sites associated with a target gene correlated with greater gene activation in TTC1240 cells (Fig. 3f ) and G401 cells (Supplementary Fig. 7d ). Given that clusters of enhancers mediate the greatest degrees of gene activation, we sought to determine whether BAF47 activates only enhancers or super-enhancers. We found that this widespread enhancer activation upon rescue of BAF47 occurs at both typical enhancers (12,875) and super-enhancers (283) and that both typical and super-enhancers are retained in the absence of BAF47 (Fig. 3g and Supplementary  Fig. 7e,f) , in contrast to previous reports 35 .
We then performed chromosome conformation capture followed by massively parallel sequencing (Hi-C) in VA-ES-BJ cells to determine whether BAF47 rescue affects global chromatin topology independently A r t i c l e s of proliferative arrest, which has been suggested as a mechanism of oncogenesis in other cancers 41, 42 . While we found that BAF47 had no significant impact on global genome architecture ( Supplementary  Fig. 8a-e) , we identified new promoter-enhancer interactions at gained enhancers such as CDKN1A (Supplementary Fig. 8f) , possibly due to downstream effects of enhancer activation. These results collectively suggest that BAF47 has a key role in mediating activation of constituent enhancers at both typical and super-enhancer clusters, with large clusters of de novo-gained BAF complex target sites promoting greatest gene activation.
Enhancer activation is mediated by BAF, not PBAF, complexes
Mammalian SWI/SNF complexes exist in two different assemblies: canonical BAF complexes and polybromo-containing BAF (PBAF) complexes. The two are defined by distinct subunits (Fig. 4a) but share the BAF47 core subunit. Given that both BAF and PBAF complexes remain intact in the absence of BAF47 (Fig. 4b) , we performed ChIP-seq for SS18 (BAF complex-specific) 43 and BAF200 (ARID2; PBAF complex-specific) to determine how rescue of BAF47 influences the targeting of each complex. SS18-marked complexes exhibited substantially greater gains in chromatin occupancy than BAF200 over gained BAF complex sites, mirroring those of BRG1 and BAF155 (Fig. 4c) . SS18-marked BAF complexes showed a dramatic gain of occupancy at distal sites, whereas gains in BAF200-marked PBAF complexes were almost entirely restricted to proximal sites (Fig. 4d-f and Supplementary Fig. 9a ). We measured log 2 fold changes in BRG1, SS18, and BAF200 occupancy upon BAF47 reintroduction and found that BRG1 and SS18 showed high correlation (PCC = 0.88), whereas BRG1 and BAF200 exhibited a substantially more modest correlation (PCC = 0.49) (Fig. 4g,h and Supplementary  Fig. 9b ). BRG1 and BAF200 showed stronger correlations at proximal sites (0.56) than at distal sites (0.43), whereas BRG1 and SS18 correlations were similar (proximal PCC = 0.82, distal PCC = 0.86), suggesting a greater role for retargeting of PBAF complexes to FC) ) for BRG1 and SS18 (g) and BRG1 and BAF200 (h) over all TTC1240 BRG1-BAF155 sites in empty or BAF47 conditions. (i) Example ChIP-seq tracks for BRG1, SS18, BAF200, H3K27ac, and RNA-seq at the VIM locus in TTC1240 cells. n = 3 biological replicates.
Experiments were repeated at least twice for each cell line.
proximal sites (Supplementary Fig. 9c,d) . These results demonstrate a disproportionate targeting of BAF complexes to enhancers and PBAF complexes to promoters, with BAF47 driving widespread enhancer activation by BAF complexes (Fig. 4i) .
BAF47 rescues BAF complex-mediated resolution of bivalency
Loss of the opposition between BAF complexes and Polycomb repressive complex 2 (PRC2) has been extensively implicated in MRT, suggesting mechanisms of global regulatory opposition 28 and locusspecific opposition (e.g., at the p16 INK4A locus) 26 . However, to date, BAF-PRC2 complex opposition has not been studied at a genomewide level. We performed ChIP-seq for SUZ12 (a core PRC2 subunit) and H3K27me3 and found that over all promoters, occupancy of BAF and PBAF complexes correlated with H3K4me3 occupancy as well as gene expression, whereas H3K27me3 and SUZ12 exhibited highest occupancy at nonexpressed genes ( Fig. 5a and Supplementary  Fig. 10a-h ). This suggests that BAF and PBAF complexes have a maintenance role at active promoters, even in the absence of BAF47. We found a set of bivalent promoters in TTC1240 cells, marked by both H3K4me3 and H3K27me3, with 3,022 (12.57%) genes categorized as bivalent ( Fig. 5a and Supplementary Fig. 10i,j) . Gene Ontology (GO) term analysis of genes with bivalent promoters strongly enriched for genes involved in kidney and neural development, likely reflecting the initiation of cell lineage-specific regulation (Fig. 5b) . We also performed ChIP-seq analyses for SUZ12 and H3K27me3 in G401 cells and found, similarly to our results in TTC1240 cells, that 2,470 (10.27%) genes were bivalent. Notably, the majority (1,902) of these bivalent genes were shared between G401 and TTC1240 cell lines ( Fig. 5c and Supplementary Fig. 10k,l) , suggesting a concordant, lineage-specific set of bivalent genes in MRT cell lines.
Given that recent studies have demonstrated efficacy of EZH2 inhibitors in MRT cell lines 34 and that EZH2 inhibitors may work through activating bivalent genes 33 , we sought to determine whether BAF47 rescue results in altered bivalent promoter regulation. We found a marked increase in target gene occupancy upon rescue of BAF47, in both BAF and PBAF complexes ( Fig. 5d and Supplementary  Fig. 11a) . Notably, while only 8.03% of conserved BRG1 target genes were bivalent in TTC1240 cells, 30.13% of gained BRG1 target genes were bivalent (Fig. 5e) A r t i c l e s of BAF47, the greatest percentage increase of any promoter category (Supplementary Fig. 11b ). We next aimed to assess whether the number of bivalent genes was affected by rescue of BAF47. We found that 506 (16.7%) genes that were bivalent in TTC1240 cells in control conditions were no longer bivalent in BAF47 conditions (Fig. 5f) , suggesting a role for BAF complex-mediated activation at these specific sites upon rescue with BAF47. Examining all BRG1-BAF155 sites in TTC1240 cells in BAF47 conditions, we found that rescue of BAF47 led to a gain in BAF complex occupancy and a decrease in H3K27me3 occupancy, and that this occurred predominantly at promoter proximal sites ( Supplementary   Fig. 11c-e) . Over all bivalent promoters in TTC1240 cells, we observed a major decrease in H3K27me3 but no changes in H3K4me3 (Fig. 5g and Supplementary Fig. 11f) , suggesting the regulation of bivalency is due solely to regulation of Polycomb-mediated repression, in contrast to previous findings 26 . Over bivalent promoters, we observed a gain in both BAF and PBAF complex occupancy ( Fig. 5h  and Supplementary Fig. 11f) . Notably, log 2 fold change values over proximal TTC1240 BRG1-BAF155 sites showed opposition of BRG1 and H3K27me3 (PCC = −0.26) and of SS18 and H3K27me3 (PCC = −0.24), but opposition was greater between BAF200 and H3K27me3 (PCC = −0.40) (Fig. 5i and Supplementary Fig. 11g-i) similar results in G401 cells (Supplementary Fig. 12 ), but opposition of Polycomb-mediated repression was more modest in EpS cell lines, which contain fewer bivalent promoters (Supplementary Fig. 13 ), suggesting that the contribution of bivalency to oncogenesis may vary by tissue of origin. Our results demonstrate that both BAF and PBAF complex assemblies have critical roles in resolving bivalent promoters to activation in development and that this process is substantially impaired by BAF47 loss, which leads to reformation of bivalency and repression of key developmental and lineage-specific differentiation genes.
Collaborative activation of bivalent promoters and enhancers
Having identified two mechanisms through which BAF47 affects gene activation, by both BAF and PBAF complexes, we sought to determine the relative contribution of each mechanism in gene regulation and subsequent tumor suppression. We performed RNA-seq on G401 and TTC1240 cell lines with either empty vector or BAF47 (Supplementary Fig. 14a,b) . We found that bivalent genes were overrepresented in the 2,635 significantly regulated genes in TTC1240 cells, with 20.80% marked as bivalent (Fig. 6a) . We found that 13.99% of all bivalent genes were upregulated by BAF47, the largest proportion of any gene category, and that bivalent genes showed net upregulation when compared to H3K4me3-only genes (Fig. 6b) . We observed similar effects in G401 cells (Supplementary Fig. 14c,d ).
We identified a set of 642 genes that were significantly and concordantly regulated in both G401 and TTC1240 cells (Fig. 6c,d) . Gene-set enrichment analysis (GSEA) and GO term analyses showed that upregulated genes have critical roles in kidney development and epithelial-mesenchymal transition (EMT), suggesting these as key pathways involved in BAF47-mediated tumor suppression (Fig. 6e,f and Supplementary Fig. 14e-h) , which would correspond with mechanisms of mesenchymal-epithelial transition (MET) in sarcomagenesis 44 and roles for BAF47 in EMT of pancreatic cancer 45 . We did not observe the previously suggested 28 downregulation of EZH2 or upregulation of CDKN2A genes in TTC1240, suggesting this is specific to certain cell lines (Supplementary Fig. 14i,j) . Increases in BAF complex occupancy and decreases in PRC2-mediated repression were specific to the promoters of upregulated genes upon BAF47 rescue (Supplementary Fig. 15a-f) . These results suggest that while MRTs are heterogeneous and multi-origin tumors, critical cellular processes such as EMT may be regulated by BAF47-containing BAF complexes and altered in sarcomagenesis driven by BAF47 loss.
We next sought to determine how regulation of enhancers and bivalent promoters cooperate to control gene regulation. We categorized genes by the number of conserved (empty-BAF47) and gained (BAF47-only) distal BAF complex sites and found overrepresentation of bivalent genes among those with greater numbers of gained distal BAF complex sites ( Fig. 6g and Supplementary Fig. 14k ), and these genes corresponded to the upregulation described above (Fig. 3f) . This collaborative activation is exemplified at the CTGF and FN1 loci, at which these activated genes gain (i) promoter occupancy that resolves bivalency to activation and (ii) numerous distal BAF complex-activated enhancers (Fig. 6h,i) . We demonstrate here that these enhancer and promoter regulatory functions are hallmarks of BAF47-mediated gene regulation and tumor suppression, and that a critical collaborative role for these two distinct BAF complex functions is lost in BAF47-deficient cancers.
DISCUSSION
Mutations in the genes encoding BAF complexes are recurrent in more than 20% of human cancers and in several developmental disorders. Here we show that loss of a core BAF complex subunit, BAF47, dramatically impairs the chromatin affinity and regulation of BAF complexes without impairing in-solution assembly or subunit stability (Fig. 7a) . We show that BAF complexes have a critical role in mediating enhancer state and activation, as well as in resolving bivalent promoters to activation through opposition of Polycomb-mediated repression, and that these activities collaborate in BAF47-driven gene activation and tumor suppression in MRT cell lines (Fig. 7b) . Our data suggest a broad-reaching role for BAF complexes in directing cell state through regulation of developmental enhancers and bivalent promoters that may contribute to numerous cancers and developmental disorders characterized by BAF complex perturbations.
Understanding the role of BAF47 in the stability and assembly of BAF complexes has been a challenge in the field, with some studies suggesting little change in complex composition 29, [37] [38] [39] and others suggesting dramatic loss of stability 35, 36 upon BAF47 loss. We did not find global changes in BAF complex stability or assembly, in agreement with recent yeast studies, which show largely retained SWI/SNF assembly but loss of ATPase function upon loss of Snf5 (ref. 46) . The structural integrity of BAF47-deficient residual BAF complexes shown here supports previous observations of BRG1 dependency in MRT cell lines 39 and suggests therapeutic avenues for targeting these intact residual BAF complexes in MRT. Our results suggest that this dependency is due to a retained and required regulation by BAF and PBAF complexes, largely at active promoters, in the absence of BAF47.
The opposition between BAF and Polycomb complexes is a critical mechanism that has been extensively implicated, through genetic and mechanistic studies, in cancer 23, 26, 28, 29 . Our results reaffirm the BAF complex as a Trx-group protein through opposition of Polycombmediated repression. This study substantiates how BAF complexes, within the existing dynamics of Trx or PcG proteins, drive resolution of bivalent promoters toward activation 32 . These results help to explain the observed efficacy of EZH2 inhibitors in BAF47-deficient sarcomas and suggest a mechanistic synergy between EZH2 inhibition and BAF47 rescue, particularly in the control of bivalent promoters demonstrate a broad role for BAF complexes at both bivalent promoters and enhancers, which, when perturbed, may explain the outsized role for this complex in human disease.
We establish here that BAF47 drives a widespread gain of BAF complex occupancy that mediates enhancer state as well as enhancer activation. Our results suggest that the BAF complex has a pioneering role in governing enhancer state and activation, such that BAF47 restores the functional ability of the BAF complex to bind to and activate distal regulatory sites. As such, recruitment by transcription factors or other regulators fails to create BAF complex targeting and activation in the absence of BAF47, as previously shown with Arid1a loss promoting regeneration 47 . Enhancers have co-occupancy of numerous chromatin remodelers and regulators 10, 48 , and our results suggest a dynamic regulation of enhancers by both activating (BAF complex) and repressive (NuRD complex) 49 remodelers that may be occurring in a manner similar to histone acetyltransferases and histone deacetylases 50 . Interruption of this regulatory dynamic via BAF47 loss may then decommission a large number of enhancers in the MRT genome, further supporting a critical pioneering role for BAF complexes at enhancers.
In summary, our studies demonstrate that reintroduction of BAF47 in BAF47-deficient cells triggers a dual gain of BAF complex-mediated activation at enhancers and bivalent promoters. We demonstrate that the enhancer activation and resolution of bivalency to activation are collaborative, leading to activation of key genes involved in cell fate determination and tumor suppression. Further studies will be required to determine the ordering and relative contributions of these functions in the tumor suppression pathway. Our data suggest multiple defining roles for the BAF complex in chromatin activation at enhancers and bivalent promoters, each of which could be independently or collaboratively perturbed in other BAF complex-driven cancers. Taken together, these data have important implications for the outsized contribution of BAF complex aberrations in human malignancy and developmental disorders.
URLs. GSEA, http://www.broadinstitute.org/gsea.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. Vector and cloning information. C-terminal V5-tagged BAF47 (SMARCB1) constitutive expression in MRT and EpS cell lines was achieved using lentiviral infection of an EF1α-driven expression vector (modified from Clontech, dual promoter EF-1a-MCS-PGK-Blast), selected with blasticidin (1 µg/µl).
Lentiviral generation.
Lentivirus was produced by PEI (Polysciences Inc.) transfection of HEK293T LentiX cells (Clontech) with gene delivery vector co-transfected with packaging vectors pspax2 and pMD2.G as previously described 23 . Supernatants were harvested 72 h after transfection and centrifuged at 20,000 r.p.m. for 2 h at 4 °C. Virus-containing pellets were resuspended in PBS and placed on cells dropwise. Selection of lentivirally infected cells was achieved with either blasticidin or puromycin, both used at 2 µg/ml. Nuclear extract. Nuclear extract (NE) preparation and IP studies were performed as described previously 6 . Briefly, trypsinized cells were incubated in buffer A (25 mM HEPES, pH 7.6, 5 mM MgCl 2 , 25 mM KCl, 0.05 mM EDTA, 10% glycerol and 0.1% NP40 with protease inhibitor (Roche), 1 mM DTT and 1 mM phenylmethylsulfonyl fluoride (PMSF)) for 10 min, and the pellets were resuspended in 600 µl buffer C (10 mM HEPES, pH 7.6, 3 mM MgCl 2 , 100 mM KCl, 0.5 mM EDTA and 10% glycerol with protease inhibitor, 1 mM DTT and 1 mM PMSF) with 67 µl 3 M (NH 4 ) 2 SO 4 for 20 min. The lysates were spun down in an ultracentrifuge at 10,000 r.p.m. at 4 °C for 10 min. Nuclear extracts were precipitated with 200 µg (NH 4 ) 2 SO 4 on ice for 20 min and purified as pellets by ultracentrifugation at 10,000 r.p.m. at 4 °C for 10 min. The pellets were resuspended in IP Buffer (150 mM NaCl, 50 mM Tris-HCl, pH 7.5, 1 mM EDTA and 1% Triton X-100 with protease inhibitor, 1 mM DTT and 1 mM PMSF) for the subsequent experiments. For the RIPA and IP buffer comparison experiments performed, nuclear pellets were resuspended in either RIPA buffer (150 mM NaCl, 50 mM Tris-HCl, pH 7.5, 1% Nonidet P-40, 0.5% sodium deoxycholate, and 0.1% SDS, complete with protease inhibitor, 1 mM DTT, and 1 mM PMSF) or IP buffer (same as above, except 300 mM NaCl). To analyze the localization of the protein, NE-PER Nuclear and Cytoplasmic Extraction Reagents (#78833, Thermo Scientific) were used according to the manufacture's protocol. The details of the antibodies used for immunoblotting are presented in Supplementary Table 3. Immunoprecipitation. For immunoprecipitation, 150-300 µg of nuclear extract was incubated with 1.25 µg of antibody in IP buffer overnight. Samples were incubated with Dynabeads (Thermo Scientific) for 2 h. Beads were washed three times with IP buffer and twice with BC100 (20 mM HEPES, 100 mM KCl, 0.2 mM EDTA, 10% glycerol), and eluted with 20 µl of sample buffer (NuPage LDS buffer (1×, (Thermo Scientific)) and 100 mM DTT).
SMARCB1 knockout by CRISPR-Cas9 genome editing. The SMARCB1 locus was targeted by the Ini1 CRISPR-Cas9 KO Plasmid and Ini1 HDR Plasmid (Santa Cruz Biotechnology sc-423027; sc-423027-HDR) in HEK293T Lenti-X cells (Clontech) following the manufacturer's protocol. Specifically, 5 million HEK293T cells were co-electroporated with two plasmids (2 µg DNA/plasmid) using the Amaxa Biosystems Nucleofector I and Amaxa Cell Line Nucleofector Kit V. After nucleofection, cells were expanded for 48 h and GFP + /RFP + cells (expressing both the KO and HDR plasmids) were single-cell sorted by FACS.
Single-cell clones were expanded further and screened through immunoblotting for identification of successful knockouts. Two-dimensional liquid chromatography-mass spectrometry IP proteomics. Four samples for each cell type were prepared (two IgG controls and two replicates of anti-BRG1 IPs) for mass spectrometry analysis (label-free quantification). Eluted proteins from each condition were processed simultaneously to reduce sample variability. Proteins were reduced, alkylated, digested with trypsin, and desalted using offline C18 reversed-phase chromatography. Purified peptides were separated by online C18 reversed-phase chromatography and analyzed in a top10 collision-induced dissociation data-dependent manner using an LTQ-Velos mass spectrometer 51 .
Two-dimensional liquid chromatography-mass spectrometry IP proteomics data processing and analysis. Data analysis was performed with MaxQuant software 52 , supported by a database search engine for peptide identification (human IPI). Label-free quantification algorithms were added to MaxQuant by extracting isotope patterns for each peptide in each run.
Density sedimentation analyses. Nuclear extract (500 µg) was resuspended in 200 ml 0% glycerol HEMG buffer and carefully overlaid onto a 10 ml 10-30% glycerol (in HEMG buffer) gradient prepared in a 14 × 89 mm polyallomer centrifuge tube (331327, Beckman Coulter). Tubes were centrifuged in an SW40 rotor at 4 °C for 16 h at 40,000 r.p.m. Fractions (0.5 ml) were collected and used in analyses.
Urea denaturation studies. Nuclear extracts (150 µg) were subjected to partial urea denaturation in 0.25 to 5.0 M urea (in IP buffer), for 15 min at room temperature before anti-BRG1 IP. The co-precipitated proteins were analyzed by immunoblotting.
Differential salt extraction. Cell types were grown under standard conditions. Following collection of 5 × 10 7 cells, cells were suspended in elution buffer (50 mM Tris-HCl at pH 7.5, 1 mM EDTA, 0.1% NP40) supplemented with protease inhibitor mixture (Roche) and 1 mM PMSF, incubated on ice for 5 min, and centrifuged. Supernatant was collected, and the pellet was suspended in elution buffer with 150 mM NaCl. This process was repeated sequentially with increasing concentrations of NaCl to collect 0, 150, 300, 500, and 1,000 mM NaCl soluble fractions. Each fraction, including the total (5 × 10 6 cells in elution buffer) and pellet (material remaining following 1,000 mM NaCl extraction) fractions, was prepared in SDS (final concentration of 1%), quantified by Pierce BCA Protein Assay Kit (Thermo Fisher Scientific), and analyzed (1.5 µg of protein) by immunoblot. Quantitative densitometry analyses were performed with the Li-Cor Odyssey Imaging System (Li-COR Biosciences).
ChIP-seq data collection. Cells were harvested following 48-h exposure to the lentivirus and 5-d selection with 10 µg/ml of blasticidin for chromatin immunoprecipitation (ChIP) experiments. ChIP experiments were performed per standard protocols (Millipore) with minor modifications. Briefly, cells were cross-linked for 10 min with 1% formaldehyde at 37 °C. Five million fixed cells were used per chromatin immunoprecipitation experiment. This reaction was subsequently quenched with 125 mM glycine for 5 min. Antibodies used for ChIP studies are listed in Supplementary Table 3. RNA data collection. Cells were harvested following 48-h exposure to the lentivirus and either 1-d (day 3 after infection) or 5-d (day 7 after infection) selection with 10 µg/ml blasticidin for RNA-seq experiments. RNA-seq samples were prepared in biological duplicate (independent lentiviral production, infection, selection, and cell culture). All RNA was obtained using the RNeasy Mini Kit (Qiagen).
Proliferation experiments. 20,000 cells were plated after 48-h exposure to the lentivirus and 48-h selection with 10 µg/ml of blasticidin, with day 0 denoting the day cells were plated after infection and selection. The numbers of viable cells in three wells were measured using Vi-CELL Cell Viability Analyzer (Beckman Coulter) on days 1, 3, 5, and 7. method 68 , similarly to the study by Rao et al. 67 . Sixth, we recovered the interaction matrices with bin size = 50 kb by combining every 10 bins into one bin with bin mode = mean. The differential heat map was the difference between the matrices in the two conditions. Analysis for topological associating domains (TADs). Each chromosome was separated into 50-kb bins, and an interaction matrix of each chromosome was generated for Hi-C data. The interaction matrix was normalized by KR normalization 68 . The normalized interaction matrix was used as input for identifying TAD by Armatus 69 .
Data availability. The sequencing data sets generated and/or analyzed in the current study have been deposited in the Gene Expression Omnibus (GEO) repository under accession GSE90634. A Life Sciences Reporting Summary is available.
